Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
5(45%)
Results Posted
20%(1 trials)

Phase Distribution

Ph early_phase_1
1
9%
Ph phase_1
1
9%
Ph phase_2
6
55%
Ph phase_3
3
27%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(5)

Detailed Status

Recruiting5
Completed5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (9.1%)
Phase 11 (9.1%)
Phase 26 (54.5%)
Phase 33 (27.3%)

Trials by Status

recruiting545%
completed545%
not_yet_recruiting19%

Recent Activity

5 active trials
Showing 5 of 11
recruitingphase_3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
not_yet_recruitingphase_2

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

NCT07060001
recruitingearly_phase_1

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

NCT07059975
recruitingphase_2

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

NCT07187193
recruitingphase_2

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

NCT07078591
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07007312Phase 3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Recruiting
NCT07060001Phase 2

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Not Yet Recruiting
NCT07059975Early Phase 1

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Recruiting
NCT07187193Phase 2

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

Recruiting
NCT07078591Phase 2

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Recruiting
NCT06742463Phase 2

VHAG in Treating R/R T-ALL/LBL

Recruiting
NCT00002835Phase 3

Combination Chemotherapy in Treating Patients With Lymphoma

Completed
NCT00333840Phase 3

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Completed
NCT00002833Phase 2

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Completed
NCT00004263Phase 1

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed
NCT00556127Phase 2

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11